Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-β on the cell surface

Blood

Volumn 117, Issue 12, 2011, Pages 3382-3390

  Chung, Jin Sung ^a   Shiue, Lisa H ^b   Duvic, Madeleine ^b   Pandya, Amit ^a   Cruz Jr , Ponciano D ^a   Ariizumi, Kiyoshi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEPARAN SULFATE; IMMUNOGLOBULIN G; INTEGRIN; LIGAND; MESSENGER RNA; PROTEOGLYCAN; SYNDECAN 4; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MEMORY CELL; MYCOSIS FUNGOIDES; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY SYNDROME; SKIN DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 79953075757     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-302034     Document Type: Article

References (48)

1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143(7):854-859.
2. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and MF arise from distinct T cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767-771.
3. Berger CL, Edelson RL. Current concepts of the immunobiology and immunotherapy of cutaneous T cell lymphoma: insights gained through crosstalk between the clinic and the bench. Leuk Lymphoma. 2003;44(10):1697-1703. (Pubitemid 37221043)
4. Wong BY, Gregory SA, Dang NH. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest. 2007;25(6):495-501. (Pubitemid 47450676)
5. Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(3):575-583. (Pubitemid 43255644)
6. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3(3):193-215. (Pubitemid 34533779)
7. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
8. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268. (Pubitemid 33706004)
9. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4(7):670-679. (Pubitemid 36874444)
10. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6(1):90-98. (Pubitemid 40136700)
11. Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4(11):1093-1101. (Pubitemid 37428037)
12. Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245- 1252. (Pubitemid 43045636)
13. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
14. Pistillo MP, Tazzari PL, Palmisano GL, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003;101(1):202-209. (Pubitemid 36025909)
15. Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T cells from patients with Mycosis fungoides-cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(1):212-219. (Pubitemid 43336115)
16. Shikano S, Bonkobara M, Zukas PK, Ariizumi K. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem. 2001;276(11):8125-8134.
17. Weterman MA, Ajubi N, van Dinter I, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60(1):73-81.
18. Safadi FF, Xu J, Smock SL, et al. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biol. 2001;84(1):12-26. (Pubitemid 33101507)
19. Metz RL, Patel PS, Hameed M, Bryan M, Rameshwar P. Role of human HGFIN/nmb in breast cancer. Breast Cancer Res. 2007;9(5):R58.
20. Chung JS, Sato K, Dougherty I, Cruz PD Jr, Ariizumi K. DC-HIL is a negative regulator of T lymphocyte activation. Blood. 2007;109(10):4320-4327. (Pubitemid 46743399)
21. Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol. 2007;179(9):5778-5784.
22. Chung JS, Bonkobara M, Tomihari M, Cruz PD Jr, Ariizumi K. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol. 2009;39(4):965-974.
23. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med. 1981;154(5):1403-1418. (Pubitemid 12235188)
24. Starkebaum G, Loughran TP Jr, Waters CA, Ruscetti FW. Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor. Int J Cancer. 1991;49(2):246-253.
25. Popovic M, Sarin PS, Robert-Gurroff M, et al. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science. 1983;219(4586):856- 859. (Pubitemid 13194772)
26. Kaltoft K, Bisballe S, Dyrberg T, et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol. 1992;28A(3 Pt 1):161-167.
27. Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382-1388.
28. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435-471. (Pubitemid 34800227)
29. Ishiguro K, Kadomatsu K, Kojima T, et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem. 2001;276(50):47483-47488.
30. Santanche S, Bellelli A, Brunori M. The unusual stability of saporin, a candidate for the synthesis of immunotoxins. Biochem Biophys Res Commun. 1997;234(1):129-132. (Pubitemid 27267546)
31. Akdis CA, Akdis M, Simon H-U, Blaser K. Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int Arch Allergy Immunol. 1999;118(2-4):140-144. (Pubitemid 29195489)
32. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/ dipeptidylpeptidase IV. Blood. 2006;107(3):1108-1115. (Pubitemid 43156312)
33. Fuhlbrigge RC, Kiefler JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997;389(6654):978-981. (Pubitemid 27485690)
34. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+CD26- subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144(1):125-135. (Pubitemid 32154603)
35. Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma. 2008;8(suppl 5):S187-S192.
36. Baciu PC, Saoncella S, Lee SH, et al. Syndesmos, a protein that interacts with the cytoplasmic domain of syndecan-4, mediates cell spreading and actin cytoskeletal organization. J Cell Sci. 2000;113(Pt 2):315-324. (Pubitemid 30088976)
37. David G, Bai XM, Van der SB, Cassiman JJ, Van den BH. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 1992;119(4):961-975.
38. Kure S, Yoshie O, Aso H. Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. Jpn J Cancer Res. 1987;78(11):1238-1245. (Pubitemid 18012967)
39. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J. 2004;20(1):71-78. (Pubitemid 38392180)
40. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105(4):1640-1647. (Pubitemid 40223685)
41. Nikolova M, Tawab A, Marie-Cardine A, et al. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. J Invest Dermatol. 2001;116(5):731-738. (Pubitemid 32467652)
42. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 1991;64(5):867-869. (Pubitemid 121001173)
43. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem. 1997;272(29):18000-18006. (Pubitemid 27306378)
44. Feige JJ, Negoescu A, Keramidas M, Souchelnitskiy S, Chambaz EM. Alpha 2-macroglobulin: a binding protein for transforming growth factor-beta and various cytokines. Horm Res. 1996;45(3-5):227-232. (Pubitemid 26079714)
45. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7(10):1118-1122. (Pubitemid 33010019)
46. Miyazono K. TGF-beta receptors and signal transduction. Int J Hematol. 1997;65(2):97-104.
47. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+) CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629-644. (Pubitemid 32844773)
48. Tanaka Y, Kimata K, Wake A, et al. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J Exp Med. 1996;184(5):1987-1997. (Pubitemid 26404488)